Persistent nocturnal cough: randomised controlled trial of high dose inhaled corticosteroid.

Arch Dis Child

Queen Elizabeth Hospital for Children, Royal Hospitals Trust, Hackney Road, London E2 8PS, UK.

Published: July 1999

Objective: To investigate the effect of a short course of inhaled corticosteroid in the treatment of isolated and persistent nocturnal cough in children.

Design: Randomised double blind placebo controlled study.

Setting: Subjects' homes in east London, England.

Subjects: Consecutively referred children, 1-10 years old, with persistent nocturnal cough.

Interventions: Placebo or fluticasone propionate 1 mg twice daily for three nights and 500 microg twice daily for 11 nights. Videotaping of children at night: two nights' baseline, nights 3 and 4 after three days of inhaled corticosteroid, and nights 15 and 16.

Main Outcome Measure: A fall in 75% of coughs from baseline.

Results: 50 subjects were recruited. The median number of coughs in the baseline period for the inhaled corticosteroid group and placebo group were 92 and 71, respectively (p = 0.43) and, on nights 15 and 16, 8 and 36, respectively (p < 0. 01). Compared to baseline, both groups of subjects improved significantly by nights 15 and 16 (p < 0.01; p < 0.01). Comparing the inhaled corticosteroid and placebo groups, coughs fell to a median of 22% and 57% of baseline totals on nights 3 and 4, respectively (p = 0.38), and 8% and 35% on nights 15 and 16, respectively (p = 0.02). 17 of 24 subjects on inhaled corticosteroid who completed the study and 8 of 23 on placebo improved by 75% after two weeks (p = 0.03).

Conclusions: Children with persistent nocturnal cough improve in two weeks after referral on placebo. There is a modest benefit from a two week course of high dose inhaled corticosteroid.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1717983PMC
http://dx.doi.org/10.1136/adc.81.1.38DOI Listing

Publication Analysis

Top Keywords

inhaled corticosteroid
28
persistent nocturnal
16
nocturnal cough
12
high dose
8
dose inhaled
8
nights
8
inhaled
7
corticosteroid
7
placebo
6
persistent
4

Similar Publications

Recent Advances and New Therapeutic Goals in the Management of Severe Asthma.

Intern Med

January 2025

Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Japan.

Asthma is characterized by chronic airway inflammation as its primary pathological condition, which leads to various respiratory symptoms due to airway narrowing, with type 2 inflammation playing a central role. Asthma treatment, primarily centered on inhaled corticosteroids, aims to suppress type 2 inflammation and improve airway narrowing. However, severe asthma that cannot be controlled with high-dose inhaled corticosteroids or other asthma medications remains a clinical issue.

View Article and Find Full Text PDF

Prevalence and features of allergic bronchopulmonary aspergillosis, United States, 2016-2022.

PLoS One

January 2025

Asthma and Air Quality Branch, Division of Environmental Health Science and Practice, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.

The epidemiology of allergic bronchopulmonary aspergillosis (ABPA) in the United States is not well-described. To estimate national ABPA prevalence among patients with asthma or cystic fibrosis, characterize ABPA testing practices, and describe ABPA clinical features, treatment, and 6-month outcomes. We used the 2016-2022 Merative™ MarketScan® Commercial/Medicare and Multi-State Medicaid Databases to identify cohorts of patients with 1) asthma, 2) cystic fibrosis (CF), and 3) ABPA.

View Article and Find Full Text PDF

[Characteristics of type 2 inflammation in nocturnal asthma and evaluation of the effectiveness of inhaled corticosteroids combination therapy].

Zhonghua Yi Xue Za Zhi

January 2025

Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou510515, China.

To investigate the characteristics of type 2 inflammation in patients with nocturnal asthma, and analyze the improvement of asthma symptoms after the use of inhaled corticosteroids (ICS) combined with different long-acting bronchodilators. Data of 231 asthma patients who first visited the Respiratory and Critical Care Medical Clinic of Nanfang Hospital of Southern Medical University from January 2020 to June 2023 and had positive bronchodilator tests (BDT), were retrospectively analyzed. These patients were divided into nocturnal asthma group and non-nocturnal asthma group based on the presence or absence of nocturnal symptoms.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!